Greywolf Therapeutics
Tom McCarthy is an accomplished entrepreneur and leader in the biotechnology sector, currently serving as Founder and Executive Chairperson of multiple companies, including Molecule to Medicine, Lucia Bio, ThirtyFiveBio, Pathios Therapeutics, and Grey Wolf Therapeutics. With a strong focus on developing innovative treatments for various medical conditions, Tom established Molecule to Medicine in 2016 to drive the co-creation and scaling of biotech ventures. Tom has also played pivotal roles in other organizations, such as Orbit Discovery, Brandon Capital Partners, and previously held positions with Kea Therapeutics and Trigemina, Inc. Notably, Tom served as President, CEO, and Managing Director at Spinifex Pharmaceuticals, where a strategic vision was implemented that transitioned the company from a university spinout to a global clinical development entity specializing in pain management therapies.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.